Skip to content
OpenCapital
Get started

Avanos Medical AVNS Liabilities For Estimated Rebates And Incentives, Net

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B+108%
Enterprise value$1.24B+105%
P/S1.6×+0.8×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept avns:LiabilitiesForEstimatedRebatesAndIncentivesNet.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's liabilities for estimated rebates and incentives, net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's liabilities for estimated rebates and incentives, net?
Avanos Medical (AVNS) reported liabilities for estimated rebates and incentives, net of $11.1M in Q1 2026.
How has Avanos Medical's liabilities for estimated rebates and incentives, net changed year-over-year?
Avanos Medical's liabilities for estimated rebates and incentives, net decreased by 50.0% year-over-year, from $22.2M to $11.1M.
What is the long-term trend for Avanos Medical's liabilities for estimated rebates and incentives, net?
Over 4 years (2021 to 2025), Avanos Medical's liabilities for estimated rebates and incentives, net has grown at a -14.4% compound annual growth rate (CAGR), from $24.6M to $13.2M.